Achieve Life Sciences, Inc. reported a net loss of $54.6 million for the fiscal year ending December 31, 2025, compared to a net loss of $39.8 million in 2024. The company's total operating expenses increased to $54.9 million from $39.1 million in the previous year, primarily driven by higher general and administrative costs associated with preparations for the commercial launch of its product candidate, cytisinicline. Research and development expenses remained relatively stable at $23.0 million, reflecting ongoing clinical trials and related activities. As of December 31, 2025, Achieve had cash, cash equivalents, and marketable securities totaling $36.4 million, with a positive working capital balance of $30.8 million.
The company has made significant strides in its regulatory journey, with the FDA accepting its New Drug Application (NDA) for cytisinicline as a treatment for smoking cessation in September 2025. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 20, 2026, although there are concerns regarding potential delays due to observations made during a recent FDA inspection of a third-party manufacturer involved in the NDA. Achieve has partnered with Adare Pharma Solutions for the manufacturing of cytisinicline, aiming to mitigate supply chain risks and reduce costs associated with international importation.
In terms of operational metrics, Achieve Life Sciences has focused on expanding its market presence, particularly in the U.S. and Europe, where it aims to address the nicotine dependence epidemic. The company has also received Breakthrough Therapy designation from the FDA for cytisinicline for nicotine e-cigarette cessation, which is expected to expedite its development and review process. However, Achieve faces substantial competition in the smoking cessation market, with existing products and potential new entrants posing challenges to its market share.
Looking ahead, Achieve Life Sciences acknowledges substantial doubt regarding its ability to continue as a going concern, primarily due to its reliance on raising additional capital to fund ongoing operations and clinical development. The company plans to pursue various financing options, including equity offerings and potential collaborations, to support its commercialization efforts. The financial outlook remains uncertain, with the need for significant capital to sustain operations and advance the development of cytisinicline.
About ACHIEVE LIFE SCIENCES, INC.
Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company dedicated to combating nicotine dependence through its product candidate, cytisinicline. Targeting the 29 million U.S. smokers and 11 million e-cigarette users, Achieve aims to address a significant health crisis. With FDA Breakthrough Therapy Designation, cytisinicline is positioned to become the first new prescription treatment for smoking cessation in nearly two decades, offering a promising solution with a favorable safety profile.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.